Bevacizumab (Avastin) fails to improve survival for newly diagnosed glioblastoma patients

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

Fuente : http://www.eurekalert.org/pub_releases/2014-02/uom...